CD4 T cell deficiency or defective IFNγ signaling render humans and mice
highly susceptible to Mycobacterium tuberculosis (Mtb)
infection. The prevailing model is that Th1 CD4 T cells produce IFNγ to
activate bactericidal effector mechanisms of infected macrophages. Here we test
this model by directly interrogating the effector functions of Th1 CD4 T cells
required to control Mtb in vivo. While Th1 CD4 T cells specific for the Mtb
antigen ESAT-6 restrict in vivo Mtb growth, this inhibition is independent of
IFNγ or TNF and does not require the perforin or FAS effector pathways.
Adoptive transfer of Th17 CD4 T cells specific for ESAT-6 partially inhibited
Mtb growth while Th2 CD4 T cells were largely ineffective. These results imply a
previously unrecognized IFNγ/TNF independent pathway that efficiently
controls Mtb and suggest that optimization of this alternative effector function
may provide new therapeutic avenues to combat Mtb through vaccination.
BackgroundAntigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific antigens for immunodiagnosis. In the present study, recombinant protein Rv1985c from RD2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (TB) infection among BCG-vaccinated individuals.MethodsT-cell response to Rv1985c was evaluated by IFN-γ ELISPOT in 56 TB patients, 20 latent TB infection (LTBI) and 30 BCG-vaccinated controls in comparison with the commercial T-SPOT. TB kit. Humoral response was evaluated by ELISA in 117 TB patients, 45 LTBI and 67 BCG-vaccinated controls, including all those who had T-cell assay, in comparison with a commercial IgG kit.ResultsRv1985c was specifically recognized by cellular and humoral responses from both TB and LTBI groups compared with healthy controls. Rv1985c IgG-ELISA achieved 52% and 62% sensitivity respectively, which outperformed the sensitivity of PATHOZYME-MYCO kit (34%) in detecting active TB (P = 0.011), whereas IFN-γ Rv1985c-ELISPOT achieved 71% and 55% sensitivity in detecting active and LTBI, respectively. Addition of Rv1985c increased sensitivities of ESAT-6, CFP-10 and ESAT-6/CFP-10 combination in detecting TB from 82.1% to 89.2% (P = 0.125), 67.9% to 87.5% (P < 0.001) and 85.7% to 92.9% (P = 0.125), respectively.ConclusionsIn conclusion, Rv1985c is a novel antigen which can be used to immunologically diagnose TB infection along with other immunodominant antigens among BCG-vaccinated population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.